LBL-034 is an investigational GPRC5D-targeted CD3 bispecific antibody. The Food and Drug Administration (FDA) has granted Orphan Drug designation to LBL-034 for the treatment of multiple myeloma.
The FDA has granted Fast Track Designation to RPTR-1-201 for unresectable or metastatic triple-negative breast cancer after ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果